Scholarlink

<p>Obesity and associated chronic diseases are major challenges to good health globally. Therapies based on probiotic modalities are rapidly gaining attention. The current study highlights the strain-specific effects of probiotics <i>Lacticaseibacillus rhamnosus</i> GG ATCC 53103 (LR), <i>Lactiplantibacillus plantarum</i> ATCC 8014 (LP), and <i>Lactobacillus delbrueckii</i> subsp. <i>lactis</i> ATCC 12315 (LD) on obesity, metabolic health, and gut microbiota in C57BL/6 mice on either a high-fat diet (23.71% fat) or standard diet (5.5% fat). Eight groups were assessed over eight weeks with or without probiotic supplementation. LR in the HFD cohort (LR-H) demonstrated the greatest efficacy, reducing weight gain by 25.1% (6.26 ± 0.61&#xa0;g vs. 8.36 ± 1.02&#xa0;g), visceral adipose tissue (VAT) by 11.1% (2.16 ± 0.10&#xa0;g vs. 2.43 ± 0.12&#xa0;g), and liver weight by 11.4% (3.03 ± 0.10&#xa0;g vs. 3.42 ± 0.12&#xa0;g) compared with the HFD group. Metabolic improvements included reductions in serum glucose (20.7%), triacylglycerol (TG) (23.5%), cholesterol (8.9%), low-density lipoprotein (LDL) (13.2%), and alanine transaminase (ALT) (63.4%). LR also decreased leptin and lipopolysaccharide (LPS) levels by 24.1% and 16.2%, suggesting reduced inflammation. Gut microbiota analysis revealed increased Firmicutes and beneficial genera (<i>Lactobacillus</i>, <i>Allobaculum</i>). LP and LD showed lesser effects, with weight gains of 8.04 ± 0.98&#xa0;g and 7.21 ± 1.15&#xa0;g, respectively. The superior efficacy of LR highlights its potential for obesity management, meriting further clinical exploration.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Strain-Specific Lactobacillus Probiotics Intervention in Mitigating Obesity and Metabolic Dysregulation via Gut Microbiota Modulation in a Mouse Model of High-Fat Diet

  • 期刊论文

  • 发表日期：

    2025年8月29日

查看全文
  • Ehsan Shad,
  • Farnoosh Azadikhah,
  • Shahram Shekarforoush,
  • Saeed Nazifi,
  • Mohammad Hadi Eskandari

摘要

Obesity and associated chronic diseases are major challenges to good health globally. Therapies based on probiotic modalities are rapidly gaining attention. The current study highlights the strain-specific effects of probiotics Lacticaseibacillus rhamnosus GG ATCC 53103 (LR), Lactiplantibacillus plantarum ATCC 8014 (LP), and Lactobacillus delbrueckii subsp. lactis ATCC 12315 (LD) on obesity, metabolic health, and gut microbiota in C57BL/6 mice on either a high-fat diet (23.71% fat) or standard diet (5.5% fat). Eight groups were assessed over eight weeks with or without probiotic supplementation. LR in the HFD cohort (LR-H) demonstrated the greatest efficacy, reducing weight gain by 25.1% (6.26 ± 0.61 g vs. 8.36 ± 1.02 g), visceral adipose tissue (VAT) by 11.1% (2.16 ± 0.10 g vs. 2.43 ± 0.12 g), and liver weight by 11.4% (3.03 ± 0.10 g vs. 3.42 ± 0.12 g) compared with the HFD group. Metabolic improvements included reductions in serum glucose (20.7%), triacylglycerol (TG) (23.5%), cholesterol (8.9%), low-density lipoprotein (LDL) (13.2%), and alanine transaminase (ALT) (63.4%). LR also decreased leptin and lipopolysaccharide (LPS) levels by 24.1% and 16.2%, suggesting reduced inflammation. Gut microbiota analysis revealed increased Firmicutes and beneficial genera (Lactobacillus, Allobaculum). LP and LD showed lesser effects, with weight gains of 8.04 ± 0.98 g and 7.21 ± 1.15 g, respectively. The superior efficacy of LR highlights its potential for obesity management, meriting further clinical exploration.